Targeting FLT3 Positive AML with New & Improved Therapies with Dr. Margaret Kasner

Event Description

About 30% of acute myeloid leukemia patients have developed a mutation in the FLT3 gene. Up until recently, this specific mutation usually resulted in poor treatment outcomes. Today, we have several drugs designed to directly target this mutation and even more progress is occurring with newer drugs and various treatment combinations in clinical trials.

Dr. Kasner, an AML expert from the Sidney Kimmel Cancer Center at Thomas Jefferson University, will summarize key developments and clinical trials currently underway for FLT3 positive AML. If you have a FLT3 mutation, this radio show episode is definitely for you. 


Schedule & Agenda

01:00PM - 02:00PM
Katie Braswell
Welcome, announcements and introduction
Dr. Kasner
Dr. Kasner will explain the major clinical trials currently underway for testing existing and novel drugs designed to target the FLT3 mutation found in acute myeloid leukemia.
Question and Answer Session
Audience is able to call in to the radio show (515) 602-9728 to ask Dr. Kasner questions about what was discussed during our interview today.

Speakers & Moderators

The author Katie Braswell
Katie Braswell
Dallas, Texas

Katie joined the HealthTree Foundation as the Community Director for AML in 2021. She is a registered dietitian who previously worked at the VA hospital in Dallas, Texas where she coached veterans with blood cancer on how to use nutrition to improve their treatment outcomes and minimize cancer-related side effects. Katie is passionate about health education and patient empowerment. In her spare time, she loves to experiment with new recipes in the kitchen, spend time running outdoors and travel to new places.

The author Margaret Kasner, MD
Margaret Kasner, MD
Philadelphia, Pennsylvania

Associate Professor of Medical Oncology in the Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation Division, Section Leader of the Leukemia Program in the Department of Medical Oncology and Co-Medical Director at the Clinical Trials Office, Sidney Kimmel Cancer Center at Thomas Jefferson University

Have Any Questions?

Thank you for your interest in the event. If you have any question, we would love to help! Just fill out the form below and we will get back to you as quickly as possible.


Get In Touch With Us


(800) 930-5159



Get the latest thought leadership on AML delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life with AML stories, AML clinical trials, AML 101 articles and events with AML experts.

Thanks to our HealthTree Community for AML Sponsors:

Bristol Myers Squibb
Jazz Pharmaceuticals

Follow Us

facebook instagram twitter youtube


Terms of Use and Privacy Policy     Newsroom     About    Donations    Find an AML Specialist     Newsletter     Learn     Connect


Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / HealthTree for AML is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811